Oncos Therapeutics raises € 4 million to develop oncolytic viruses into cancer treatments

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million investment from HealthCap, which is one of the largest specialized providers of venture capital within life sciences in Europe.

After treating 200 late stage cancer patients since 2007 with strong safety and efficacy results, Oncos has selected its modified oncolytic adenovirus CGTG-102 as its lead clinical candidate.

— The results have been strong for late stage solid tumor cancers where routine therapies have failed. Time is critical in the treatment of cancer. We are confident that when treating earlier stage patients, our oncolytic virus therapy will prove even more significant, says Research Professor Akseli Hemminki, CSO and co-founder of the company, and a research group leader at the University of Helsinki.

— Oncolytic viruses are maturing as a new treatment modality in cancer. Oncos, as one of the leading companies in the field, combines very promising results in humans with strong science, comments Dr Johan Christenson, partner with HealthCap.

Oncos Therapeutics develops new cancer therapies based on its next generation oncolytic viruses. The company’s unique Advanced Therapy Access Program was started in 2007 for cancer patients in whom standard-of-care therapies have failed.

Today, 200 patients have undergone individually tailored oncolytic virus therapy suggesting strong safety and efficacy. The program is based on extensive scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.

Read more from HUB:
A cancer-eating virus